Apollomics vs Outlook Therapeutics
Apollomics is the larger business, with $8.5m of revenue in fiscal 2025 against $1.4m for Outlook Therapeutics (6.0 times as much). Apollomics kept more of each dollar of sales as profit: a net margin of -128.7% against -4416.2%.
| Latest fiscal year | ApollomicsAPLM, 2025 | Outlook TherapeuticsOTLK, 2025 |
|---|---|---|
| Revenue | $8.5m | $1.4m |
| Revenue growth | — | -82.6% |
| Net income | −$10.9m | −$62.4m |
| Operating margin | — | — |
| Net margin | -128.7% | -4416.2% |
| Return on equity | — | — |
| Free cash flow | −$10.4m | −$51.8m |
| Cash | $3.3m | $8.1m |
| Total debt | $0 | $29.9m |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 17 |
| Market value | $30.1m | $86.1m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 5 buys, 0 sales | 10 buys, 0 sales |